Drug Eluting Stents:The Next Vioxx
December 14, 2006
Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org
1. DES whether used on or off label will likely require life long anticoagulation with Plavix like drugs.
2. The incidence of late thrombosis is significant when anticoagulation is interrupted for events such as elective surgery.
3. Unlike restenosis following insertion of a bare metal stent which rarely results in death to the patient, late thrombosis following use of a DES results in a 50% mortality.
4. Hints of this problem were present during FDA presentations prior to DES approval which may lead to significant liability as this problem becomes more apparent.
Page : 11 to 1 of 1
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011